Bio
Carmen Di Giovanni is an expert in molecular modeling and computational approaches for drug discovery, with a PhD in Pharmaceutical Sciences. She works at the Department of Pharmacy of the University of Naples Federico II, where her research focuses on the design and optimization of novel therapeutic compounds targeting infertility, cancer, metabolic diseases. She has strong expertise in structure- and ligand-based drug design, molecular dynamics simulations, and ADME prediction, integrating computational and experimental strategies to elucidate biomolecular mechanisms and support the development of innovative therapies. She is the author of 39 peer-reviewed publications in leading scientific journals and actively collaborates in multidisciplinary national and international research projects, contributing to advancements at the interface of computational pharmacology and experimental science.

Bio
Thomas R. Caulfield, Jr., PhD is the Founder and CEO of Digital Ether Computing LLC, an AI-powered drug discovery and advanced AI systems company based in Miami. He previously served as Associate Professor across seven Mayo Clinic departments simultaneously and directed the institution's core drug discovery facility for 12 years, supporting 30+ collaborating laboratories. His research spans computational chemistry, molecular dynamics, generative molecular design, and physics-informed AI, with 110+ publications, 65+ patents, and an h-index of 41. He has published in Neuron, Science Translational Medicine, and Nature Communications, and serves as reviewer for Nature and Science.

Bio
Professor Niazi has pioneered the field of biological drugs by creating biosimilars, mRNA vaccines, CRISPR technology, and applications of AI and quantum mechanics in drug discovery. He has published over 100 peer-reviewed articles on these topics, helped the US FDA rationalize its approval guidelines, and served as an advisor to multiple heads of state on topics ranging from regulatory controls to governance philosophies. He has published 70+ books, owns 100+ US patents, and has raised over a billion dollars to supporgivingesearch programs.